Charles S. Irving
Dr. Irving is a key advisor at Cell Cure Neurosciences. He served as the CEO of Cell Cure Neurosciences from 2006 until 2017, during which time he was responsible for bringing OpRegen from the research lab to the bedside and establishing the company’s manufacturing capabilities. He continues to bring to the company his vast experience in the development of human embryonic stem cell based products and retinal pigment epithelial cell transplantation. He has a Ph.D. in Chemistry from the Weizmann Institute of Science. Before switching from academia to biotech product development, Dr. Irving was an Associate Professor in the Department of Pediatrics at the Baylor College of Medicine in Houston, Texas. Dr. Irving also brings to Cell Cure Neurosciences valuable managerial skills, having been COO of a subsidiary of a US medical device company for nine years, as well as Vice President of Clinical and Regulatory Affairs and VP of Business Development of an Israeli startup medical device company. Dr. Irving’s management experience also includes leading another Israeli biotech company from the stage of in-licensing academic technology through cGMP production to Phase I/II clinical trials and the successful out-licensing of its biologic product.